Synaffix and Sotio Biotech sign $740M ADC licensing deal

Synaffix, a Lonza subsidiary, has signed a licensing deal with Sotio Biotech worth up to $740 million, allowing Sotio to use Synaffix's ADC technology for one bioconjugate program, with potential expansion to two more.

“Lonza’s Synaffix is adding another manufacturing licensing partnership by securing a $740 million deal with Sotio Biotech, which would allow Sotio to use the Dutch company’s three-pronged ADC tech.”endpoints.news

• 1 source
• endpoints.newsSynaffix joins forces with Sotio on $740M ADC licensing deal, plans expansion after Lonza acquisitionAnna BrownOct 16, 2023

Summarized from public sources; check the original articles before acting on it.